Pitt-Ohio State Clinical Trials Unit Administrative Supplement

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3UM1AI069494-14S1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020.0
    2021.0
  • Known Financial Commitments (USD)

    $533,144
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    . SUSAN KOLETAR
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF PITTSBURGH AT PITTSBURGH
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The University of Pittsburgh Virology Specialty Laboratory will test various samples provided (nasopharyngeal swabs, throat swabs, and saliva) using EUA approved testing platforms from ThermoFisher and Hologic for patients testing for SARS-CoV-2 to increase the United States testing capacity. Testing volume will depend on sample delivery and test kit availability. Capacity will initially approximate 25-50 samples today, ramping up to 100-200 per day with a sufficient supply chain for reagents. The Ohio State University Medical Center's Clinical Laboratories are significantly increasing their testing capacity using multiple platforms for PCR and serologic testing (e.g. CDC, DiaSorin, Abbott to name a few). Using the Medical Center's CLIA-certified testing venues, we propose to develop a protocol to identify, test and obtain clinical history from defined populations who are not in the top tier for priority testing.